Table 1 Clinico-pathological characteristics at primary diagnosis and genotype distribution
All | BCL2−938 genotype | Pvalue | ||
|---|---|---|---|---|
AC / AA | CC | |||
n (%) | 182 | 141 (77.5) | 41 (22.5) | |
Mean age (years ± SD) | 6.5 ± 4.6 | 6.3 ± 4.5 | 7.1 ± 4.6 | 0.298 |
Gender (male/female) | 111/71 | 83/58 | 28/13 | 0.276 |
Relapse | ||||
no | 137 | 105 (76.7) | 32 (23.3) | 0.640 |
yes | 45 | 36 (80.0) | 9 (20.0) | |
HSCT | ||||
no | 119 | 97 (81.5) | 22 (18.5) | 0.073 |
yes | 63 | 44 (69.9) | 19 (30.1) | |
Relapse after HSCT (n = 63) | ||||
no | 40 | 26 (65.0) | 14 (35.0) | 0.270 |
yes | 23 | 18 (78.3) | 5 (21.7) | |
Risk Group Classification | ||||
standard | 67 | 59 (88.1) | 8 (11.9) | |
medium | 72 | 53 (73.6) | 19 (26.4) | 0.008 |
high | 43 | 29 (67.4) | 14 (32.6) | |
Prednisone response (n = 174) | ||||
good | 160 | 129 (80.6) | 31 (19.4) | 0.148 |
poor | 14 | 9 (64.3) | 5 (35.7) | |
Molecular genetics (n = 176) | ||||
no aberration | 121 | 94 (77.7) | 27 (22.3) | 0.627 |
BCR/ABL fusion | 13 | 9 (69.2) | 4 (30.8) | |
TEL/AML rearrangement | 35 | 28 (80.0) | 7 (20.0) | |
MLL/AF4 rearrangement | 3 | 3 | 0 | |
TCF3/PBX1 rearrangement | 1 | 1 | 0 | |
chromosomal 9 deletion | 1 | 1 | 0 | |
hyperdiploidity | 2 | 2 | 0 | |